Evox To Raise Cash In 2018 For Novel Exosome Platform
Executive Summary
Emerging Company Profile: Evox Therapeutics – a privately held, Oxford-based biotechnology company developing a new class of biotherapeutics called exosomes – is using its technology to improve the delivery of validated therapies, particularly targeting central nervous system and neuromuscular conditions.
You may also be interested in...
Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers
Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.